# Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma

> **NCT07459608** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 75 (estimated)

## Conditions studied

- Indolent Lymphoma
- WM
- MZL
- CLL / SLL

## Interventions

- **DRUG:** Lisaftoclax

## Key facts

- **NCT ID:** NCT07459608
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07459608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07459608, "Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07459608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*